PharmaEssentia Corporation
6446
주식 순위
#1440
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
주가
$36.89
시가총액
$15.25B
변동 (1일)
-1.28%
변동 (1년)
144.12%
국가
TW
거래 PharmaEssentia Corporation (6446)
카테고리
Healthcare
PharmaEssentia Corporation (6446)의 수익
Jun 2026 기준 수익 TTM: $284.95M
PharmaEssentia Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익은 $284.95M입니다. 2023년에 회사는 $-32.16M의 수익을 올렸으며 이는 2022년의 수익 $-60.07M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
PharmaEssentia Corporation의 수익 기록 (2010 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $284.95M | 212.31% |
| 2024 | $91.24M | -383.66% |
| 2023 | $-32.16M | -46.45% |
| 2022 | $-60.07M | -40.77% |
| 2021 | $-101.42M | 46.26% |
| 2020 | $-69.34M | 146.30% |
| 2019 | $-28.15M | -17.15% |
| 2018 | $-33.98M | 15.54% |
| 2017 | $-29.41M | 12.91% |
| 2016 | $-26.05M | 0.49% |
| 2015 | $-25.92M | -3.64% |
| 2014 | $-26.90M | 35.45% |
| 2013 | $-19.86M | 125.31% |
| 2012 | $-8.81M | 31.09% |
| 2011 | $-6.72M | 17.15% |
| 2010 | $-5.74M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 519.26% |
IN
|
